Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ASCENTAGE PHARMA GROUP INTERNATIONALAAPG · Entity 4672 | Director · Chairman and CEO | May 20, 2026 | May 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ASCENTAGE PHARMA GROUP INTERNATIONAL
Report date May 20, 2026 · Filed May 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 1,193,569 |
Reported balance
After 2026-05-21 transaction · row 1
1 source rowRow 1 · 2026-05-21 · Exercise / conversion · Acquired 95,575 · Balance 1,193,569 |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Footnote (2) | 405,280 |
Reported balance
After 2026-05-21 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-05-21 · Exercise / conversion · Acquired 92,746 · Balance 405,280 F2: Shares held by Reporting Person's spouse. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. |
| Restricted stock unitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 95,575 |
Reported balance
After 2026-05-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-05-20 · Grant · Acquired 95,575 · Balance 95,575 F4: Each restricted stock unit (the "RSUs") represent a contingent right to receive one Ordinary Share of the Issuer upon vesting. The RSUs vested on 05/21/2026 and had no expiration date. |
| Restricted stock unitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-05-21 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-05-21 · Exercise / conversion · Disposed 95,575 · Balance 0 F5: Represents the vesting in full on 5/21/2026 of the RSUs granted to the Reporting Person on 05/20/2026. |
| Restricted stock unitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-05-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-05-20 · Grant · Acquired 298,195 · Balance 0 F6: The RSUs vest in four equal increments on May 21, 2027, 2028, 2029 and 2030 and have no expiration date. |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $6.58 | Direct | 298,194 |
Reported balance
After 2026-05-20 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-05-20 · Grant · Acquired 298,194 · Balance 298,194 F7: The exercise price of the options is in HKD and the exercise price included in the table represents conversion to USD based on the exchange rate as of the date of grant. The options vest in four equal increments on May 21, 2027, 2028, 2029 and 2030 and expire ten years from the date of grant. |
| Restricted stock unitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectBy Spouse | 103,365 |
Reported balance
After 2026-05-20 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-05-20 · Grant · Acquired 103,365 · Balance 103,365 F8: The RSUs vest in four equal increments on November 26, 2026, 2027, 2028 and 2029 and have no expiration date. |
| Restricted stock unitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectBy Spouse | 214,999 |
Reported balance
After 2026-05-20 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-05-20 · Grant · Acquired 214,999 · Balance 214,999 F6: The RSUs vest in four equal increments on May 21, 2027, 2028, 2029 and 2030 and have no expiration date. |
| Restricted stock unitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectBy Spouse | 92,746 |
Reported balance
After 2026-05-20 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-05-20 · Grant · Acquired 92,746 · Balance 92,746 F10: The RSUs vested on 05/21/2026 and had no expiration date. |
| Restricted stock unitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectBy Spouse | 0 |
Reported balance
After 2026-05-21 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2026-05-21 · Exercise / conversion · Disposed 92,746 · Balance 0 F11: Represents the vesting in full on 5/21/2026 of the RSUs granted to the Reporting Person's spouse on 05/20/2026. |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $6.58 | IndirectBy Spouse | 214,988 |
Reported balance
After 2026-05-20 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-05-20 · Grant · Acquired 214,988 · Balance 214,988 F7: The exercise price of the options is in HKD and the exercise price included in the table represents conversion to USD based on the exchange rate as of the date of grant. The options vest in four equal increments on May 21, 2027, 2028, 2029 and 2030 and expire ten years from the date of grant. |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $8.12 | IndirectBy Spouse | 103,364 |
Reported balance
After 2026-05-20 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-05-20 · Grant · Acquired 103,364 · Balance 103,364 F9: The exercise price of the options is in HKD and the exercise price included in the table represents conversion to USD based on the exchange rate as of the date of grant. The options vest in four equal increments on November 26, 2026, 2027, 2028 and 2029 and expire ten years from the date of grant. |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Footnote (1) | 22,054,131 |
Reported balance
Holding disclosure · report date 2026-05-20 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 22,054,131 F1: Shares held by Dajun Yang Dynasty Trust, of which the Reporting Person is the investment advisor. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Footnote (3) | 14,089,111 |
Reported balance
Holding disclosure · report date 2026-05-20 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 14,089,111 F3: Shares held by HealthQuest Pharma Limited, an entity controlled by the Reporting Person's spouse. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares held by Dajun Yang Dynasty Trust, of which the Reporting Person is the investment advisor. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
F2: Shares held by Reporting Person's spouse. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
F3: Shares held by HealthQuest Pharma Limited, an entity controlled by the Reporting Person's spouse. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
F4: Each restricted stock unit (the "RSUs") represent a contingent right to receive one Ordinary Share of the Issuer upon vesting. The RSUs vested on 05/21/2026 and had no expiration date.
F5: Represents the vesting in full on 5/21/2026 of the RSUs granted to the Reporting Person on 05/20/2026.
F6: The RSUs vest in four equal increments on May 21, 2027, 2028, 2029 and 2030 and have no expiration date.
F7: The exercise price of the options is in HKD and the exercise price included in the table represents conversion to USD based on the exchange rate as of the date of grant. The options vest in four equal increments on May 21, 2027, 2028, 2029 and 2030 and expire ten years from the date of grant.
F8: The RSUs vest in four equal increments on November 26, 2026, 2027, 2028 and 2029 and have no expiration date.
F9: The exercise price of the options is in HKD and the exercise price included in the table represents conversion to USD based on the exchange rate as of the date of grant. The options vest in four equal increments on November 26, 2026, 2027, 2028 and 2029 and expire ten years from the date of grant.
F10: The RSUs vested on 05/21/2026 and had no expiration date.
F11: Represents the vesting in full on 5/21/2026 of the RSUs granted to the Reporting Person's spouse on 05/20/2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 21, 2026 Filed May 22, 2026 20:18 UTC | ASCENTAGE PHARMA GROUP INTERNATIONAL AAPG · Entity 4672 | Exercise / conversionRestricted stock units · Derivative | 92,746 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-060585 · marketforms-73253.xml · derivative · entry 14 Yang Dajun · CIK 0002059751 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 0 Underlying: Ordinary Shares · 92,746 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · security: Represents the vesting in full on 5/21/2026 of the RSUs granted to the Reporting Person's spouse on 05/20/2026. F11 · derivative.exercise_date: Represents the vesting in full on 5/21/2026 of the RSUs granted to the Reporting Person's spouse on 05/20/2026. F11 · derivative.expiration_date: Represents the vesting in full on 5/21/2026 of the RSUs granted to the Reporting Person's spouse on 05/20/2026. Read SEC document |
| May 21, 2026 Filed May 22, 2026 20:18 UTC | ASCENTAGE PHARMA GROUP INTERNATIONAL AAPG · Entity 4672 | Exercise / conversionRestricted stock units · Derivative | 95,575 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-060585 · marketforms-73253.xml · derivative · entry 6 Yang Dajun · CIK 0002059751 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 95,575 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Represents the vesting in full on 5/21/2026 of the RSUs granted to the Reporting Person on 05/20/2026. F5 · shares: Represents the vesting in full on 5/21/2026 of the RSUs granted to the Reporting Person on 05/20/2026. F5 · derivative.exercise_date: Represents the vesting in full on 5/21/2026 of the RSUs granted to the Reporting Person on 05/20/2026. F5 · derivative.expiration_date: Represents the vesting in full on 5/21/2026 of the RSUs granted to the Reporting Person on 05/20/2026. Read SEC document |
| May 21, 2026 Filed May 22, 2026 20:18 UTC | ASCENTAGE PHARMA GROUP INTERNATIONAL AAPG · Entity 4672 | Exercise / conversionOrdinary Shares | 92,746 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-060585 · marketforms-73253.xml · nonDerivative · entry 2 Yang Dajun · CIK 0002059751 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote (2) Disclosed balance after: 405,280 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · ownership.nature: Shares held by Reporting Person's spouse. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| May 21, 2026 Filed May 22, 2026 20:18 UTC | ASCENTAGE PHARMA GROUP INTERNATIONAL AAPG · Entity 4672 | Exercise / conversionOrdinary Shares | 95,575 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-060585 · marketforms-73253.xml · nonDerivative · entry 1 Yang Dajun · CIK 0002059751 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,193,569 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:18 UTC | ASCENTAGE PHARMA GROUP INTERNATIONAL AAPG · Entity 4672 | GrantRestricted stock units · Derivative | 92,746 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-060585 · marketforms-73253.xml · derivative · entry 13 Yang Dajun · CIK 0002059751 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 92,746 Underlying: Ordinary Shares · 92,746 shares Expires not disclosed F10 · security: The RSUs vested on 05/21/2026 and had no expiration date. F10 · derivative.expiration_date: The RSUs vested on 05/21/2026 and had no expiration date. Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:18 UTC | ASCENTAGE PHARMA GROUP INTERNATIONAL AAPG · Entity 4672 | GrantOptions · Derivative | 103,364 | $0.00 Strike: $8.12 | $0.00 |
DisclosureSEC source: 0001213900-26-060585 · marketforms-73253.xml · derivative · entry 12 Yang Dajun · CIK 0002059751 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 103,364 Underlying: Ordinary Shares · 103,364 shares Expires not disclosed F9 · security: The exercise price of the options is in HKD and the exercise price included in the table represents conversion to USD based on the exchange rate as of the date of grant. The options vest in four equal increments on November 26, 2026, 2027, 2028 and 2029 and expire ten years from the date of grant. F9 · derivative.exercise_date: The exercise price of the options is in HKD and the exercise price included in the table represents conversion to USD based on the exchange rate as of the date of grant. The options vest in four equal increments on November 26, 2026, 2027, 2028 and 2029 and expire ten years from the date of grant. F9 · derivative.expiration_date: The exercise price of the options is in HKD and the exercise price included in the table represents conversion to USD based on the exchange rate as of the date of grant. The options vest in four equal increments on November 26, 2026, 2027, 2028 and 2029 and expire ten years from the date of grant. Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:18 UTC | ASCENTAGE PHARMA GROUP INTERNATIONAL AAPG · Entity 4672 | GrantOptions · Derivative | 214,988 | $0.00 Strike: $6.58 | $0.00 |
DisclosureSEC source: 0001213900-26-060585 · marketforms-73253.xml · derivative · entry 11 Yang Dajun · CIK 0002059751 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 214,988 Underlying: Ordinary Shares · 214,988 shares Expires not disclosed F7 · security: The exercise price of the options is in HKD and the exercise price included in the table represents conversion to USD based on the exchange rate as of the date of grant. The options vest in four equal increments on May 21, 2027, 2028, 2029 and 2030 and expire ten years from the date of grant. F7 · derivative.exercise_date: The exercise price of the options is in HKD and the exercise price included in the table represents conversion to USD based on the exchange rate as of the date of grant. The options vest in four equal increments on May 21, 2027, 2028, 2029 and 2030 and expire ten years from the date of grant. F7 · derivative.expiration_date: The exercise price of the options is in HKD and the exercise price included in the table represents conversion to USD based on the exchange rate as of the date of grant. The options vest in four equal increments on May 21, 2027, 2028, 2029 and 2030 and expire ten years from the date of grant. Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:18 UTC | ASCENTAGE PHARMA GROUP INTERNATIONAL AAPG · Entity 4672 | GrantRestricted stock units · Derivative | 214,999 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-060585 · marketforms-73253.xml · derivative · entry 10 Yang Dajun · CIK 0002059751 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 214,999 Underlying: Ordinary Shares · 214,999 shares Expires not disclosed F6 · security: The RSUs vest in four equal increments on May 21, 2027, 2028, 2029 and 2030 and have no expiration date. F6 · derivative.exercise_date: The RSUs vest in four equal increments on May 21, 2027, 2028, 2029 and 2030 and have no expiration date. F6 · derivative.expiration_date: The RSUs vest in four equal increments on May 21, 2027, 2028, 2029 and 2030 and have no expiration date. Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:18 UTC | ASCENTAGE PHARMA GROUP INTERNATIONAL AAPG · Entity 4672 | GrantRestricted stock units · Derivative | 103,365 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-060585 · marketforms-73253.xml · derivative · entry 9 Yang Dajun · CIK 0002059751 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 103,365 Underlying: Ordinary Shares · 103,365 shares Expires not disclosed F8 · security: The RSUs vest in four equal increments on November 26, 2026, 2027, 2028 and 2029 and have no expiration date. F8 · derivative.exercise_date: The RSUs vest in four equal increments on November 26, 2026, 2027, 2028 and 2029 and have no expiration date. F8 · derivative.expiration_date: The RSUs vest in four equal increments on November 26, 2026, 2027, 2028 and 2029 and have no expiration date. Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:18 UTC | ASCENTAGE PHARMA GROUP INTERNATIONAL AAPG · Entity 4672 | GrantOptions · Derivative | 298,194 | $0.00 Strike: $6.58 | $0.00 |
DisclosureSEC source: 0001213900-26-060585 · marketforms-73253.xml · derivative · entry 8 Yang Dajun · CIK 0002059751 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 298,194 Underlying: Ordinary Shares · 298,194 shares Expires not disclosed F7 · security: The exercise price of the options is in HKD and the exercise price included in the table represents conversion to USD based on the exchange rate as of the date of grant. The options vest in four equal increments on May 21, 2027, 2028, 2029 and 2030 and expire ten years from the date of grant. F7 · derivative.exercise_date: The exercise price of the options is in HKD and the exercise price included in the table represents conversion to USD based on the exchange rate as of the date of grant. The options vest in four equal increments on May 21, 2027, 2028, 2029 and 2030 and expire ten years from the date of grant. F7 · derivative.expiration_date: The exercise price of the options is in HKD and the exercise price included in the table represents conversion to USD based on the exchange rate as of the date of grant. The options vest in four equal increments on May 21, 2027, 2028, 2029 and 2030 and expire ten years from the date of grant. Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:18 UTC | ASCENTAGE PHARMA GROUP INTERNATIONAL AAPG · Entity 4672 | GrantRestricted stock units · Derivative | 298,195 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-060585 · marketforms-73253.xml · derivative · entry 7 Yang Dajun · CIK 0002059751 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 298,195 shares Expires not disclosed F6 · security: The RSUs vest in four equal increments on May 21, 2027, 2028, 2029 and 2030 and have no expiration date. F6 · derivative.exercise_date: The RSUs vest in four equal increments on May 21, 2027, 2028, 2029 and 2030 and have no expiration date. F6 · derivative.expiration_date: The RSUs vest in four equal increments on May 21, 2027, 2028, 2029 and 2030 and have no expiration date. Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:18 UTC | ASCENTAGE PHARMA GROUP INTERNATIONAL AAPG · Entity 4672 | GrantRestricted stock units · Derivative | 95,575 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-060585 · marketforms-73253.xml · derivative · entry 5 Yang Dajun · CIK 0002059751 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,575 Underlying: Ordinary Shares · 95,575 shares Expires not disclosed F4 · security: Each restricted stock unit (the "RSUs") represent a contingent right to receive one Ordinary Share of the Issuer upon vesting. The RSUs vested on 05/21/2026 and had no expiration date. F4 · derivative.expiration_date: Each restricted stock unit (the "RSUs") represent a contingent right to receive one Ordinary Share of the Issuer upon vesting. The RSUs vested on 05/21/2026 and had no expiration date. F4 · balance_after: Each restricted stock unit (the "RSUs") represent a contingent right to receive one Ordinary Share of the Issuer upon vesting. The RSUs vested on 05/21/2026 and had no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.